2000 - 2005
2005
- The poxviral scrapin MV-LAP requires a myxoma viral infection context to efficiently downregulate MHC-I molecules. (online-abstract)
Collin N., Guerin J.-L., Drexler I., Blanie S., Gelfi J., Boullier S., Foucras G., Sutter G., Messud-Petit F.
Virology, 343, 171-178 (2005) - Modified vaccinia virus Ankara protein F1L is a novel BH3-domain binding protein and acts together with the early viral protein E3L to block virusassociated apoptosis. (pdf, 1 MB)
Fischer S., Ludwig H., Holzapfel J., Kvansakul M., Chen L., Huang D.C.S., Sutter G., Kneese M., Häcker G.
Cell Death Differ., 13, 109-118 (2005) - Inactivation of the viral interleukin 1ß receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. (pdf, 340 KB)
Staib C., Kisling S., Erfle V., Sutter G.
J. Gen. Virol., 86, 1997-2006 (2005) - Melanoma patients respond to a new HLA-A*01-presented antigenic ligand derived from a multiepitope region of melanoma antigen TRP-2. (online-abstract)
Paschen A., Jing W., Drexler I., Klemm M., Song M., Müller-Berghaus J., Xuan Duc Nguyen X. D., Osen W., Stevanovic S., Sutter G., Schadendorf D.
Int. J. Cancer, 116, 944-948 (2005) - Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: Correlations with neutralizing antibodies and cytotoxic T cells. (pdf, 450 KB)
Quinnan G., Yu X., Lewis M., Zhang P., Sutter G., Silvera P., Dong M., Choudhary A., Sarkis P., Bouma P., Zhang Z., Montefiori D., VanCott T., Broder C.
J. Virol., 79, 3358-3369 (2005) - Role of viral factor E3L in vaccinia virus MVA infection of human cells-regulation of the virus life cycle and identification of differentially expressed host genes. (pdf, 540 KB)
Ludwig H., Mages J., Staib C., Lehmann M., Lang R., Sutter G.
J. Virol., 79, 2584-2596 (2005) - A phase I vaccination study with tyrosinase inpatients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). (online-abstract)
Meyer R., Britten C., Siepmann U., Petzold B., Sagban T., Lehr H., Weigle B., Schmitz M., Mateo L., Schmidt B., Bernhard H., Jakob T., Hein R., Schuler G., Schuler-Thurner B., Wagner S., Drexler I., Sutter G., Arndtz N., Chaplin P., Enk A., Huber C., Wölfel T.
Cancer Immunol. Immunother., 54, 453-467 (2005)
2004
- Modified vaccinia virus Ankara as antigen delivery system: how can we use its potential? (online-abstract)
Drexler I., Staib C., Sutter G.
Curr. Opin. Biotechnol., 15, 506-512 (2004) - Protective and disease-enhancing immune responses induced by recombinant modified vaccinia virus Ankara expressing respiratory synzytial virus proteins. (online-abstract)
Olszewska W., Suezer Y., Sutter G., Openshaw P.
Vaccine, 23, 215-221 (2004) - Vaccine protection from CD4+ T –cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens. (pdf, 200 KB)
Koopman G., Mortier D., Hofman S., Niphuis H., Fagrouch Z., Norley S., Sutter G., Liljeström P., Heeney J. L.
J. Gen. Virol., 85, 2915-2924 (2004) - Enhanced cellular immunity and systemic control of SHIV infection ba combinaed parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. (pdf, 540 KB)
Makitalo B., Lundholm P., Hinkula J., Nilsson C., Karlen K., Morner A., Sutter G., Erfle V., Heeney J., Wahren B., Biberfeld G., Thorstensson R.
J. Gen. Virol. 85, 2407-2419 (2004) - Construction and isolation of recombinant MVA. (online-abstract)
Staib C., Drexler I., Sutter G.
Methods Mol. Biol., 269, 77-100 (2004) - Neutralization assay using a modified vaccinia virus Ankara vector expressing the green florescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus. (pdf, 300 KB)
Cosma A., Bühler S., Nagaraj R., Staib C., Hammarin A., Wahren B., Goebel F., Erfle V., Sutter G.
Clin. Diagn. Lab. Immunol., 11, 406-410 (2004) - HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. (pdf, 260 KB)
Hermann F., Lehr H.-A., Drexler I., Sutter G., Hengstler J., Wollscheid U., Seliger B.
Cancer Res., 64, 215-220 (2004) - Partial tyrosinase-specific self tolerance by HLA-A*0201 –restricted cytotoxic T lymphocytes in mice and man. (online-abstract)
Lotz C., Ferreira E.A., Drexler I., Mutallib S.A., Huber C., Sutter G., Theobald M.
Int. J. Cancer, 108, 571-579 (2004) - Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro. (pdf, 54 KB)
Fleischer K., Schmidt B., Kastenmüller W., Busch D.H., Drexler I., Sutter G., Heike M., Peschel C., Bernhard H.
J. Immunol., 172, 162-169 (2004)
2003
- Multispecific vaccine-induced mucosal cytotoxic T Iymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. (pdf, 1,5 MB)
Vogel T., Reynolds M., Fuller D., Vielhuber K., Shipley T., Fuller J.F., Kunstman K., Sutter G., Marthas M., Erfle V., Wolinsky S., Wang C., Allison D., Rud E., Wilson N., Montefiori D., Altman J., Watkins D.
J. Virol., 77, 13348-13360 (2003) - Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cellstransduced ex vivo with a recombinant replication-deficient vaccinia vector encording the human tyrosinase gene: A phase I trial. (online-abstract)
DiNicola M., Carlo-Stella C., Anichini A., Mortarini R., Guidetti A., Tragni G., Gallino F., Del Vecchio M., Ravagnani F., Morelli D., Chaplin P., Arndtz N., Sutter G., Drexler I., Permiani G., Cascinelli N., Gianni A.
Hum. Gene. Ther., 14, 1347-1360 (2003) - Therapeutic vaccination with recombinant modified vaccinia virus Ankara-HIV-1 nef elicits a strong Nef specific T –helper cell response in chronic HIV infected individuals. (online-abstract)
Cosma C., Nagaraj R., Bühler S., Hinkula J., Busch D., Sutter G., Goebel F., Erfle V.
Vaccine, 22, 21-29 (2003) - Vaccinia vectors as candidate vaccines: The development of modified vaccinia virus Ankara for antigen delivery. (online-abstract)
Sutter G., Staib C.
Curr. Drug Target Infect. Disord., 3, 263-271 (2003) - Live viral vectors: Vaccinia virus. (online-abstract)
Staib C., Sutter G.
Methods Mol. Med., 87, 51-68 (2003) - Functional role of human leukocyte antigen-G up regulation renal cell carcinoma. (pdf, 180 KB)
Bukur J., Rebmann V., Grosse-Wilde H., Ruebben H., Drexler I., Sutter G., Huber C., Seliger B.Cancer Res., 63, 4107-4111 (2003) - Replication of modified vaccinia virus Ankara in primary chicken embryofibroblasts requires expression of the interferon resistance gene E3L. (pdf, 2 MB)
Hornemann S., Harlin O., Staib C., Kisling S., Erfle V., Kaspers B., Häcker G., Sutter G.
J. Virol., 77, 8394-8407 (2003) - Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vacciniavirus: IHD-J is most efficient in TGN-wrapping and EEV release. (pdf, 710 KB)
Meiser A., Boulanger D., Sutter G., Krijnse Locker J.
J. Gen. Virol., 84, 1383-1392 (2003) - Improved host range selestion for recombinant modified vaccinia virus Ankara. (online-abstract)
Staib C., Löwel M., Erfle V., Sutter G.
Bio Techniques, 34, 694-700 (2003) - Human papillpmavirus type 16 L1 capsomeres induced L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. (pdf, 470 KB)
Öhlschläger P., Osen W., Dell K., Faath S., Garce R. L., Jochmus I., Müller M., Pawlita M., Schäfer K., Sehr P., Staib C., Sutter G., Gissmann L.
J. Virol., 77, 4635-4645 (2003) - Identification of vaccinia virus epitope-specific HLA-A*0201 –restricted T cells and comparative analysis of smallpox vaccines. (pdf, 310 KB)
Drexler I., Staib C., Kastenmüller W., Stevanovic C., Schmidt B., Lemonnier F., Rammensee H., Busch D., Bernhard H., Erfle V., Sutter G.
PNAS USA, 100, 217-222 (2003) - Impaired transporter associated with antigen processing (TAP) function attributable to a single amino acid alteration in the peptide TAP subunit TAP1. (pdf, 790 KB)
Ritz U., Drexler I., Sutter G., Abele R., Huber C., Seliger B.
J. Immunol., 170, 941-946 (2003) - IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. (pdf, 250 KB)
Bronte V., Serafini P., De Santo C., Marigo I., Tosello V., Mazzoni A., Segal D., Staib C., Löwel M., Sutter G., Colombo M., Zanovello P.
J. Immunol., 170, 270-278 (2003)
2002
- Evaluation in rhesus macaques of Tat and Rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. (online-abstract)
Verrier B., Le Grand R., Ataman-Önal Y., Terrat C., Guillon C., Durand P., Hurtrel B., Aubertin A.-M., Sutter G., Erfle V., Girard M.
DNA Cell Biol., 21, 653-658 (2002) - Differences between SIV-specific T cell epitopes recognized after immunization and after infection. (pdf, 1,7 MB)
Vogel T., Horton H., Fuller D., Carter D., Vielhuber K., O`Connor D., Shipley T., Fuller J., Sutter G., Erfle V., Wilson N., Picker L., Watkins D.
Immunol., 169, 4511-4521 (2002) - Generation of recombinant fowlpox virus using the non-essential F11L orthologue as insertion site and a fast transient selection strategy. (online-abstract)
Boulanger D., Baier R., Erfle V., Sutter G.
J. Virol. Meth., 106, 141-147 (2002) - Comparison of the efficavy of early versus late viral proteins in vaccination against SIV. (online-abstract)
Stittelaar K., Gruters R., Schutten M., van Baalen C., van Amerongen G., Cranage M., Liljeström P., Sutter G., Osterhaus A.
Vaccine, 20, 2921-2927 (2002) - Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad SIV-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. (pdf, 2,4 MB)
Horton H., Vogel T., Carter D., Vielhuber K., Fuller D., Shipley T., Fuller J., Kunstman K., Sutter G., Montefiori D., Erfle V., Desrosiers R., Wilson N., Picker L., Wolinsky S., Wang C., Allison D., Watkins D.
J. Virol., 76, 7187-7202 (2002) - Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. (pdf, 120 KB)
Allen T., Mortara L., Mothe B., Liebl M., Jing P., Calore B., Piekarczyk M., Ruddersdorf R., O`Connor D., Wang X., Wang C., Allison D., Altman J., Sette A., Desrosiers R., Sutter G., Watkins D.
J. Virol., 76, 4108-4112 (2002) - Full-length core sequence dependent complex-type glycosylation of hepatitis C virus E2 glycoprotein. (pdf, 310 KB)
Zhu L., Liu J., Li Y., Kong Y., Staib C., Sutter G., Wang Y., Li G.
World J. Gastroenterol., 8, 499-504 (2002) - Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunideficiency virus infection and delay disease progression in macaques. (pdf, 1,6 MB)
Nilsson C., Sutter G., Walther-Jallow L., ten Haaft P., Akerblom L., Heeney J., Erfle V., Böttiger P., Biberfeld G., Thorstensson R.
J. Gen. Virol., 83, 807-818 (2002) - Myxoma virus Leukemia-associated protein is responsible for MHC-I and FAS-CD95 down-regulation, and defines scrapins, a new group of surface cellular receptors abductor proteins. (pdf, 2,2 MB)
Guering J.-L., Gelfi J., Boullier S., Delverdier M., Bellanger F.-A., Bertagnoli S., Drexler I., Sutter G., Messud F.
J. Virol., 76, 2912-2923 (2002)
2001
- Novel vaccine delivery systems: Solutions to HIV vaccine dilemmas? (online-abstract)
Sutter G., Haas J.
AIDS, 15, (suppl 5), 139-145 (2001) - Immune escape of melanoma: First evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. (pdf, 150 KB)
Seliger B., Ritz U., Abele R., Bock M., Tampe R., Sutter G., Drexler I., Huber C., Ferrone S.
Cancer Res., 61, 8647-8650 (2001) - Induction of SIV-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. (pdf, 410 KB)
Sharpe S., Polyanska N., Dennis M., Sutter G., Hanke T., Erfle V., Hirsch V., Cranage M.
J. Gen. Virol., 82, 2215-2223 (2001) - Efficient induction of simian immunodeficiency virus-specific immune responses by using a novel prime-boost immunization strategy. (online-abstract)
Nilsson C., Mäkitalo B., Berglund P., Bex F., Lijeström P., Sutter G., Erfle V., ten Haaft P., Heeney J., Biberfeld G., Thorstensson R.
Vaccine, 19, 3526-3536 (2001) - Vaccination with recombinant modified vaccinia Ankara protects against measles virus infection in the mouse and cotton rat model. (online-abstract)
Weidinger G., Ohlmann M., Schlereth B., Sutter G., Niewiesk S.
Vaccine, 19, 2764-2768 (2001) - Functional evaluation of HIV/SIV Nef as superantigen. (online-abstract)
Lapatschek M.S., Dürr S., Sutter G., Wagner H., Miethke T.
Virology, 282, 329-337 (2001) - A randomized, double blind study in young healthy adults comparing cell mediated and humoral immunogenicity of influenza ISCOMTM vaccines and conventional vaccines. (online-abstract)
Rimmelzwaan G. F., Nieuwkoop N., Brandenburg A., Sutter G., Beyer W.E.P., Maher D., Bates J., Osterhaus A.D.M.E.
Vaccine, 19, 1080-1087 (2001)
2000
- A vaccine strategy utilising a combination of different chimeric vectors which share specific vaccine antigens. (online-abstract)
Heeney J.L., Koopman G., Rosenwirth B., Bogers W., Van Dijk J., Nieuwenhuis I., Niphuis H., Ten Haaft P., Hanke T., Rhodes G., Berglund P., Burny A., Bex F., Sutter G., Liljeström P.
J. Med. Primatol, 29 (3-4), 268-273 (2000) - Transpoerter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope. (pdf, 150 KB)
Wölfle C., Drexler I., Van Pel A., Thres T., Leister N., Herr W., Sutter G., Huber C., Wölfle T.
Int. J. Cancer, 88 (3), 432-438 (2000) - Transient host range selection for genetical engineering of modified vaccinia virus Ankara. (online-abstract)
Staib C., Drexler I., Ohlmann M., Wintersperger S., Erfle V., Sutter G.
Biotechniques, 28 (6), 1137-1148 (2000) - Human Tumor growth is inhibited by vaccinia virus carrying the E2 gene of bovine papilloma virus. (online-abstract)
Valdez V., Sutter G., Jose M. V., Garcia-Carranca A., Erfle V., Moreno Mendoza N., Merchant H., Rosales R.
Cancer, 88 (7), 1650-1662 (2000) - Humoral and cellular immune response to HIV-1 Nef in mice DNA immunized with non-replicating or self-replicating expression vectors. (online-abstract)
Collings A., Pitkänen J., Strengell M., Pitkänen J.I., Tähtinen M., Lagerstedt A., Hakkarainen K., Ovod V., Sutter G., Ustav M., Ustav E., Mannik A., Ranki A., Peterson P., Krohn K.
Vaccine, 18, 460-467 (2000)